MWNA
CLVS

Marshall Wace North America’s Clovis Oncology, Inc. CLVS Stock Holding History

Marshall Wace North America’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-272,991
Closed -$4.9M – 2002
2018
Q4 		$4.9M Buy
272,991
+224,331
+461% +$4.58M 0.05% 250
2018
Q3 		$1.43M Buy
+48,660
New +$1.88M 0.01% 548
2018
Q1 		– Sell
-477,557
Closed -$32.5M – 1779
2017
Q4 		$32.5M Buy
477,557
+112,137
+31% +$7.84M 0.18% 133
2017
Q3 		$30M Buy
365,420
+243,466
+200% +$19.3M 0.19% 146
2017
Q2 		$11.5M Buy
121,954
+25,862
+27% +$1.58M 0.08% 288
2017
Q1 		$6.15M Buy
+96,092
New +$5.84M 0.05% 352

Other funds holding CLVS

PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Marshall Wace North America's CLVS Position: Q1 2019 in Review

Marshall Wace North America sold out of Clovis Oncology, Inc. (CLVS) in Q1 2019, closing a stake of 272,991 shares — an estimated $4.9M sold.

Marshall Wace North America first reported a position in CLVS in Q1 2017 and held it in 6 quarters. The position peaked at $32.5M in Q4 2017. 186 funds tracked by Wall St. Rank hold CLVS as of Q1 2019.

  • Marshall Wace North America reported no remaining Clovis Oncology, Inc. position as of Q1 2019 after selling out during the quarter.
  • Marshall Wace North America sold 272,991 Clovis Oncology, Inc. shares in Q1 2019, an estimated $4.9M.
  • Marshall Wace North America first reported a position in Clovis Oncology, Inc. in Q1 2017 and held it in 6 quarters.
  • Marshall Wace North America's Clovis Oncology, Inc. position peaked at $32.5M in Q4 2017.
  • 186 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q1 2019.

Based on Marshall Wace North America's 13F filing for Q1 2019, filed 14 May 2019.